Nathaniel Brooks Horwitz

Nathaniel Brooks Horwitz has a diverse work experience in the healthcare and biotech industry. Nathaniel is currently serving as the Executive Chair & Founding CEO of Mayday.Health, a national education nonprofit focused on health education. Nathaniel played a crucial role in launching the organization, raising funding, and building a talented team.

Prior to their current role, Nathaniel worked at RA Capital Management, L.P., starting as a Corporate Development Manager in 2019. Nathaniel then progressed to roles such as Venture Associate, Principal, and Venture Partner. During their tenure, they contributed to various investment activities and played a significant role in the growth and success of the firm.

Nathaniel also co-founded GentiBio, a company specializing in cell therapies for autoimmune and inflammatory diseases. Nathaniel served as a Board Director and played a key role in the company's $1.9B deal with Bristol Myers-Squibb to develop therapies for Crohn's Disease and Ulcerative Colitis.

Similarly, they co-founded TRIANA Biomedicines, a biotech company focused on using biophysics and machine learning to design molecular glues for cancer and other diseases. Nathaniel held a position as a Board Director and played a crucial role in raising $110M in funding.

Additionally, Nathaniel co-founded Avilar Therapeutics, a company dedicated to developing extracellular degraders to combat disease-causing proteins. Nathaniel served as a Board Observer and contributed to raising $75M in funding.

Earlier in their career, Nathaniel founded Nivien Therapeutics, a VC-backed startup aimed at developing a pancreatic cancer treatment. Their efforts gained media recognition and the company was featured in publications such as The Washington Post, Forbes, and The Daily Beast.

Overall, Nathaniel Brooks Horwitz has displayed an entrepreneurial spirit and a passion for making a difference in the healthcare industry through their various ventures and leadership roles.

Nathaniel Brooks Horwitz pursued a degree in Molecular & Cellular Biology from Harvard University, completing their A.B., though specific dates for this educational experience are unavailable.